<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-104485</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCRABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long termmolecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive,and has associated cardiovascular and immunological riskfactors (AU)</dc:description>
<dc:creator>Grande, C</dc:creator>
<dc:creator>Paz-Artal, E</dc:creator>
<dc:creator>Castillo-Rama, M</dc:creator>
<dc:creator>Andrés, A</dc:creator>
<dc:creator>Morales, J. M</dc:creator>
<dc:creator>Olavarria, E</dc:creator>
<dc:creator>Marín, D</dc:creator>
<dc:creator>Martínez-Sánchez, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La leucemia mieloide crónica (LMC) es una enfermedad mieloproliferativa caracterizada por la expansión clonal de células mieloides que expresan la proteína de fusión BCR-ABL, responsable de los efectos oncogénicos de la LMC. La terapia actual en el tratamiento de LMC es el inhibidor de la BCR-ABL tirosín-kinasa, imatinib. Aunque este fármaco ha demostrado mejorar la supervivencia en pacientes con LMC, su papel en el contexto del trasplante renal no ha sido ampliamente descrito en la literatura. Presentamos un caso de remisión molecular de LMC en un varón de 55 años con un segundo trasplante renal, hepatitis C y con riesgos cardiovascularese inmunológicos asociados (AU)</dc:description>
<dc:source>Nefrologia;29(6): 604-607, nov.-dic. 2009. ilus, tab</dc:source>
<dc:identifier>ibc-104485</dc:identifier>
<dc:title xml:lang="es">Remisión molecular de una leucemia mieloide crónica en un paciente con segundo trasplante renaly hepatitis</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2359^s22080</dc:subject>
<dc:subject>^d23724</dc:subject>
<dc:subject>^d29407^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33344^s22012</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d29475^s22074</dc:subject>
<dc:subject>^d23655^s22012</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>200912</dc:date>
</metadata>
</record>
</ibecs-document>
